ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RZLT
RLMD (30) AVTX (17) CAPR (34) ALT (21) ⌘ Pro Terminal →

Rezolute Inc. (NV) (RZLT) — RQD Stock Rating Cockpit

$3.95 -4.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.91

Rezolute Inc. (NV) (RZLT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $382.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RZLT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RZLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Rezolute Inc. (NV) (NASDAQ: RZLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $3.95 (-4.13% 1D, market cap $382.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RZLT ranks #534 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RZLT compare to RLMD and AVTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RZLT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RLMD (Relmada Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $381.9M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $384.5M). Among the 5-stock peer group, RZLT leads on earnings multiple (N/A) while ALT leads on capital efficiency (-34.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RZLT?
▼

Per RZLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001509261), Rezolute Inc. (NV) generated $223.7M in revenue (+13.4% YoY), -$74.4M in net income, and -$69.1M in free cash flow against $138.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.91 (-0.93%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Cash (6)Whales (7)SEC (10)Macro (11)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$12 Bull$4 Base$3 Bear
📬 FREE RZLT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RZLT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY RZLT SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (30% of score)

FRED Regime × Technicals: 28% of 52W Range • RSI-14 at 46.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
45
Grade D$4.61-19.7% Next Q
Q2 (-2Q)
42
Grade D$3.70+11.1% Next Q
Q3 (-1Q)
40
Grade D$4.11-3.9% Next Q
Current
37
Grade D-$3.95-8.1% Hist 90D α
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RZLT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RZLT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.21) and Max Pain ($4.15) forces dealer call-delta covering toward $12.03.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RZLT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RZLT Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
46.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE28% OF RANGE
L: $1$3.95H: $11
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on RZLT

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-35.0% ROIC with 42.0% gross margin and -17.33% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (35)

10/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like RZLT
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RZLT)

  • ✓Walkthrough of RZLT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RZLT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.70%📐 HORIZONTAL RANGE
2026-11-03O $4.12H $4.12L $3.95C $3.95VOL 779.3K
RES: $5.95SUP: $3.24SMA50: $4.21SMA200: $3.90
$5.84$5.02$4.21$3.39$2.58RES $5.95SUP $3.24$3.952026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RZLT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RZLT Butterfly Map → + Track RZLT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +13.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RZLT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RZLT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RZLT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RZLT)

Health Care Rank #534 of 1015 ⚔️ RLMD vs RZLT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RZLT vs. RLMD, AVTX, CAPR, ALT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Rezolute Inc. (NV) (RZLT) ranks #534 by composite RQD confidence (37/100, grade D-) and #480 by equity capitalization ($382.1M). Within this direct 5-issuer industry benchmark cohort, RZLT leads on earnings valuation at N/A trailing P/E, while ALT leads on capital efficiency and profitability with -34.7% ROIC and — gross margin. RZLT currently leads its immediate peer cohort in composite quantitative strength at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RZLT ACTIVE
Rezolute Inc. (NV)
D- 37/100 — — -35.0% -4.13% $382.1M Benchmark Subject
RLMD
Relmada Therapeutics Inc.
E 30/100 — — -35.0% +4.07% $381.9M /rlmd-vs-rzlt →
AVTX
Avalo Therapeutics Inc.
E 17/100 — — -35.0% -3.63% $384.5M /avtx-vs-rzlt →
CAPR
Capricor Therapeutics Inc.
E 34/100 — — -35.0% -3.77% $370.9M /capr-vs-rzlt →
ALT
Altimmune Inc.
E 21/100 — — -34.7% -4.67% $396.8M /alt-vs-rzlt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001509261 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Rezolute Inc. (NV) (RZLT) reported GAAP revenue of $223.7M (+13.4% vs. FY2024 revenue of $197.2M , and +42.7% cumulative change since FY2023) , GAAP net income of -$74.4M, operating cash flow of -$69.1M, and free cash flow of -$69.1M (-20.4% YoY). On the balance sheet, RZLT closed FY2025 with $138.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $223.7M -$74.4M -$69.1M -$69.1M $138.6M —
FY2024 (FY) 2024-06-30 $197.2M -$68.5M -$57.4M -$57.4M $112.0M —
FY2023 (FY) 2023-06-30 $156.8M -$51.8M -$44.5M -$44.5M — —

3. RZLT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RZLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Rezolute Inc. (NV) (NASDAQ: RZLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $3.95 (-4.13% 1D, market cap $382.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RZLT ranks #534 in composite RQD confidence.

How does RZLT compare to RLMD and AVTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RZLT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RLMD (Relmada Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $381.9M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $384.5M). Among the 5-stock peer group, RZLT leads on earnings multiple (N/A) while ALT leads on capital efficiency (-34.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RZLT?

Per RZLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001509261), Rezolute Inc. (NV) generated $223.7M in revenue (+13.4% YoY), -$74.4M in net income, and -$69.1M in free cash flow against $138.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RZLT trading relative to its 50-day, 200-day, and 52-week technical levels?

RZLT last traded at $3.95 (-4.13% on volume of 779,261 shares), positioning the stock -6.18% below its 50-day simple moving average ($4.21) and +1.28% above its 200-day simple moving average ($3.90). Across its 52-week range of $1.07 to $11.46, RZLT sits at the 27.7% percentile with a 14-day RSI of 46.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.46 to $4.44).

Direct Sub-Reports: RZLT RQD Cockpit RZLT 12M Forecast RZLT Earnings & Move RZLT Dividends & DRIP RZLT Insiders & 13F RZLT Whale Options RZLT Profit Sankey RZLT News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

RZLT — Rezolute Inc. (NV): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Rezolute Inc. (NV) (RZLT) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $3.95 (-4.13% 1D, market capitalization $382.1M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -17.33%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Rezolute Inc. (NV) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $0.4B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Rezolute Inc. (NV) (RZLT) reported $223.7M in annual revenue (up from $197.2M in FY2024, +13.4% YoY) and -$74.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($156.8M revenue, -$51.8M net income) through FY2025, RZLT scaled operating cash flow to -$69.1M and free cash flow to -$69.1M, backed by $138.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -17.33% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $1.07 – $11.46 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), RZLT carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can RZLT sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $223.7M and free cash flow of -$69.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is RZLT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RZLT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Rezolute Inc. (NV) (RZLT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RZLT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RZLT Bull vs. Bear Conversation Board — What's Your Call at $3.95?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RZLT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RZLT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $4.98 (+26.1%)
📌 Pinned Debate

Cash rose from $8.9M to $11.9M across the two most recent reported periods, and the stock trades at a $398.5M market cap with a Beta of

Long RZLT at $3.95 targeting $4.98. Cash rose from $8.9M to $11.9M across the two most recent reported periods, and the stock trades at a $398.5M market cap with a Beta of 1.0.. Institutional whale score is 7/20 and the risk/reward vs. the $1.07 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $3.08 (-22.0%)
Spot @ $3.95

Free cash flow was negative in every reported period, with FY 2025 FCF at -$69.1M against $11.9M of cash, and the Piotroski F-Score is

I respect the product at Rezolute Inc. (NV), but the stock at $3.95 is a different story. Free cash flow was negative in every reported period, with FY 2025 FCF at -$69.1M against $11.9M of cash, and the Piotroski F-Score is 2/9.. FCF yield is -17.33% and RQD sits at 37/100 (D-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%